For discrimination between transient and permanent CH patients with gland in situ, there was no clinical or laboratory parameter including gestational age, birth weight, presentation time, age at onset of therapy, or the degree of hypothyroidism based on serum levels of TSH, fT4, and thyroglobulin. The gene discussed is TG; the disease is cyclic hematopoiesis.